



2024 CDISC + TMF
EUROPE INTERCHANGE

BERLIN

24-25 APRIL: CONFERENCE & EXPO | 22, 23, 26 APRIL: TRAININGS

Adjudication of Events and Findings

Presented by Jennifer Matri, Associate Director, GCDS, GDMS, MSD
Diana Litvan, Associate Director, GCDS, GDMS, MSD

Meet the Speakers

Jennifer Mastri



Title: Associate Director

Organization: Global Clinical Data Standards, GDMS, MSD

Jennifer Mastri is an Associate Director in Global Clinical Data Standards at MSD with over 20 years of data management experience across multiple functional areas. She is responsible for oversight and maintenance of the global library vaccine and core data standards.

Diana Litvan



Title: Associate Director

Organization: Global Clinical Data Standards, GDMS, MSD

Diana Litvan is an Associate Director in Global Clinical Data Standards at MSD for Cardiovascular TA. Prior to MSD, Diana had multiple roles including setting up large and complex studies in DMW as well as writing clinical protocols, setting up trials in Inform Central Designer and overseeing data management and data cleaning.



Agenda

1. Background
2. Industry Guidance
3. Our Custom Solution
4. Next Steps

Adjudication



What is it?

A process where independent experts evaluate suspected clinical events (e.g., endpoints) reported by the Investigator

An Adjudication Charter defines the events for adjudication, a list of required documents, and criteria for each event



Who's involved?

- **Sponsor** sends required data
- **External adjudication vendor** coordinates adjudication process
- **Adjudicator** conducts assessment

Adjudicators are qualified, independent reviewers



Why do it?

Have a consistent, independent, unbiased, blinded assessment

Reduces the variability of differences in medical assessment across study sites

How can we do this at our company?

First, we looked to see what guidance is available from industry...



Health Authority Guidance?

Standards Development Organization Guidance?



Working Group Best Practices?

White Papers or Publications?



...and we learned that
(next slide)

...There is a lack of formal industry guidance for adjudication procedures.



Therapeutic Area User Guide (TAUG) for Cardiovascular Studies

Released 17-Oct-2014

- **Guidance is out of date:**
 - Instructs to collect cardiovascular (CV) endpoints events as cardiovascular events (CE)
 - Company received agency comments that CV events should be reported as Adverse Events (AE)
 - Therefore, adjudication to FACE would no longer comply with agency requests



Global Study Data Tabulation Model Implementation Guide (SDTMIG)

- **Not able to be adopted because it's still evolving and requires new ways of working for each version:**
 - **Version 3.1.1:** initially had adjudicated data mapped to the clinical findings (CF) domain
 - **Version 3.2:** removed the clinical findings domain, replaced it with the findings about (FA) domain
 - **Version 3.3:** has findings about clinical events (FACE) domain, which is not accommodating to all TAs
 - **Version 3.4:** to be determined

...Best practices have been attempted, but the resulting guidance is still incomplete.



Working Groups

- There is no best practice available from current working groups
- Historically, no one has wanted to take on adjudication data mapping
- Adjudication data is now under evaluation & review



Best Practices for Submission of Event Adjudication

Released 18-Oct-2019

- White paper from the PHUSE team that involved multiple stakeholders and regulatory authorities to map out the common practices and challenges for submission of event adjudication data
- Leveraged to map the adjudication event assessment to the EA findings domain
- Included some, but not all company-required SDTM variables (missing variables in **red** below):

XCNAM	XCSPID	XCCAT	XCSTAT	XCSTRESN	XCMETHOD
STUDYID	XCLNKID	XCSCAT	XCREASND	XCSTRESU	XCEVAL
USUBJID	XCLNKGRP	XCOBJ	XCORRES	XCLOC	XCEVALID
SUBJID	XCTPT	XCTESTCD	XCORRESU	XCLAT	XCACPTFL
XCREFID	XCTPTNUM	XCTEST	XCSTRESC	XCDIR	

So, what did we do?

1**Identified Key Stakeholders and Subject Matter Experts**

Consulted with industry experts

2**Reviewed the EA Domain Proposal for Adjudication**

Followed a similar approach to the PHUSE white paper

3**Created a Custom Domain (XC)**

Allowed flexibility across all studies to collect AEs, Procedures, etc.

- Why XC?
- Our Company maps all custom domains to begin with “X” and incrementally names them alphabetically, which allows for easier re-evaluation and mapping as new domains become available through CDISC

Our XC custom domain was able to accommodate the inclusion of SUPPXC, which is needed for company data collection

The EA domain did not include variables needed by the company to adjudicate the data

SUPPQUAL QNAM	SUPPQUAL QLABEL	Description
XCCHNGBL	Change from Baseline	Used when result is compared to a baseline value. Values are per adjudication charter. Field can be Null.
XCCHNGPD	Change from Predose	Used when result is compared to a predose value. Values are per adjudication charter. Field can be Null.
XCAESID1	Associated AE Sponsor ID Number 1	Item to be used to capture Adverse Event Sponsor ID number(s) from the AE form for adjudication. If multiple Adverse Events, enter with a comma between numbering (i.e., 1,4,6).
XCPRSID1	Associated PR Sponsor Number 1	Item to be used to capture Procedure Sequence Number(s) from the PROC form for adjudication. If multiple Procedures, enter with a comma between numbering (i.e., 1,4,6).

Sample data mapping

		Arterial Revascularization Peripheral Adjudication Form	<input type="text" value="XCOBJ"/>
1.	Event ID		
2.	Date of Event	DD/MMM/YYYY	<input type="text" value="SUPPXC.XCADJDTC"/>
3.	Duplicate event	<p>Is this event a duplicate of an existing event?</p> <p><input type="radio"/> Yes (specify event # _____)</p> <p><input type="radio"/> No</p>	<input type="text" value="SUPPXC.XCDUPIND"/> <input type="text" value="SUPPXC.XCADRFID"/>
4.	Region of Revascularization	<p><input type="radio"/> Aorta</p> <p><input type="radio"/> Lower Extremity</p> <p><input type="radio"/> Upper Extremity</p> <p><input type="radio"/> Mesenteric</p> <p><input type="radio"/> Renal</p> <p><input type="radio"/> Other (specify _____)</p> <p><input type="radio"/> No procedure performed that meets criteria of a peripheral arterial revascularization per Charter</p>	<input type="text" value="TESTCD"/>
6.	Procedure(s)	<input type="checkbox"/> Endarterectomy	

Adjudication Mapping

XC

STUDYID	SUBJID	XCSEQ	XCREFI D	XCOBJ	XCDTC	XCNAM	XCTESTC D	XCTEST	XCORRES	XCSTRESC	XCCAT	XCLOC	ACDIR	XCEVAL
12345	10001	10011	101	PERIPHERAL REVASCLARIZA TION	20-Feb-2024	ADJUDCATI ON VENDOR	RVASCR	Revascularization Region	LOWER EXTERMI TY	LOWER EXTERMI TY	ADJUDICATION EVENT			ADJUDICATOR
12345	10009	10091	109	PERIPHERAL ISCHEMIC AMPUTATION	25-Mar-2023	ADJUDCATI ON VENDOR	AMPTLVL	Amputation Level	UPPER EXTERMI TY	UPPER EXTERMI TY	ADJUDICATION EVENT	WRIST JOINT	DISTAL	ADJUDICATOR
12345	10002	10022	102	MYOCARDIAL INFARCTION	20-Feb-2024	ADJUDCATI ON VENDOR	MI Type	TYPE 1: SPONTANEOUS MYOCARDIAL INFARCTION	STEMI	STEMI	ADJUDICATION EVENT			ADJUDICATOR

SUPPXC

STUDYID	RDOMAIN	USUBJID	IDAR	IDVAREVAL	QNAM	QLABEL	QVAL	QORIG	QEVAL
12345	XC	100001	XCSEQ	10011	XCPSPID	Associated PR Sponsor ID Number 1	3	EDT	
12345	XC	100001	XCSEQ	10011	XCADJDTCT	Assigned Adjud Event Date	10-Jan-2024	EDT	
12345	XC	100001	XCSEQ	10011	XCDUPIND	Adjudicated Event Duplicate Indicator	N	EDT	
12345	XC	100009	XCSEQ	10091	XCADJDTCT	Assigned Adjud Event Date	12-Jan-2024	EDT	
12345	XC	100009	XCSEQ	10091	XCDUPIND	Adjudicated Event Duplicate Indicator	N	EDT	
12345	XC	10002	XCSEQ	10022	XCAESID1	Associated AE Sponsor ID Number 1	2	EDT	

Adjudication Mapping

XC

STUDYID	SUBJID	XCSEQ	XCREFID	XCOBJ	XCDTC	XCNAM	XCTEST CD	XCTEST	XCORRES	XCSTRESC	XCCAT	XCEVAL
12445	20009	20091	201	CONTINUOUS ECG (HOLTER) FINDING	15-Jul-2023	ADJUDICATION VENDOR	NVTABNS	Non-VT ECG Abnormalities	QRS PROLONGATION	QRS PROLONGATION	ADJUDICATION EVENT	ADJUDICATOR
12445	20009	20092	202	CONTINUOUS ECG (HOLTER) FINDING	17-Jul-2023	ADJUDICATION VENDOR	BRPTNTYP	Brugada Pattern Type	NON-SPECIFIC BRUGADA PATTERN	NON-SPECIFIC BRUGADA PATTERN	ADJUDICATION EVENT	ADJUDICATOR
12445	20009	20093	203	VT EVENT FINDING	25-Jul-2023	ADJUDICATION VENDOR	RHYTHM	Rhythm	NSVT 4-10 BEATS	NSVT 4-10 BEATS	ADJUDICATION EVENT	ADJUDICATOR

SUPPXC

STUDYID	RDOMAIN	USUBJID	IDAR	IDVAREVAL	QNAM	QLABEL	QVAL	QORIG	QEVAL
12445	XC	20009	XCSEQ	20091	XCAMFDTCT	Assigned Med Facility Event Date	10-Jan-2024	EDT	
12445	XC	20009	XCSEQ	20091	XCDUPIND	Adjudicated Event Duplicate Indicator	N	EDT	
12445	XC	20009	XCSEQ	20091	XCCHNGBL	Change From Baseline	Y	EDT	
12445	XC	20009	XCSEQ	20092	XCCHNGPD	Change From Predose	N	EDT	
12445	XC	20009	XCSEQ	20093	XCVTDTL	Non-VT Event Details	4 beats	EDT	

Where do we go from here?

This is a sponsor-defined way of working, we'd like to adopt it via an industry standard



Define an industry standard for adjudication procedures.



The Cardiovascular TAUG should be updated



Expand the adjudication findings framework into additional therapeutic areas

What does everyone else do?

As a company, we want to hear from our fellow colleagues!

Did you implement the EA findings domain from the PHUSE white paper?

What was your experience?

How do you manage updates as guidance evolves?



Thank you!

Feel free to connect with us offline, we'd love to hear from you!

jennifer_cording@merck.com

diana.litvan@merck.com

Disclaimer and Disclosures

- *The views and opinions expressed in this presentation are those of the author(s) and do not necessarily reflect the official policy or position of CDISC.*

Abstract

Data collection of adjudicated events and findings has been challenging due to the limited guidance from standards organizations and regulatory agencies. Leading to differences in data collection and reporting approaches over the years.

The presentation will cover key points in collecting the finding and events adjudication data and the inputs used to create mapping. Review of the historical data mapping findings adjudication process was examined by the company leading up to the new solution. Using the structure and process included in the PHUSE paper Best Practices for Submission of Event Adjudication Data, Version Date 18-Oct-2019, the team looked at the adjudication findings to improve the data collection and reporting. Findings about collection for the adjudication findings map to the FACE domain and required the creation of a custom domain of XC Adjudication Findings involving cross functional collaboration between internal and external parties ensuring full traceability from end to end.